T-cell activation via CD26 and caveolin-1 in rheumatoid synovium

Modern Rheumatology

Volumn 16, Issue 1, 2006, Pages 3-13

  Ohnuma, Kei ^a   Inoue, Hiroshi ^b   Uchiyama, Masahiko ^a   Yamochi, Tadanori ^a   Hosono, Osamu ^a   Dang, Nam H ^c   Morimoto, Chikao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Inoue Hospital   (Japan)

^c NEVADA CANCER INSTITUTE   (United States)

Author keywords

Caveolin 1; CD26; Memory T cell; Rheumatoid arthritis (RA); Synovial cell

Indexed keywords

CAVEOLIN 1; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DIPEPTIDYL PEPTIDASE IV; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TETANUS TOXOID;

AMINO TERMINAL SEQUENCE; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; MOLECULAR MECHANICS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIAL FLUID; SYNOVIOCYTE; SYNOVITIS; SYNOVIUM; T LYMPHOCYTE ACTIVATION; UPREGULATION;

ANTIGEN-PRESENTING CELLS; ANTIGENS, CD26; ARTHRITIS, RHEUMATOID; CAVEOLIN 1; HUMANS; IMMUNOCONJUGATES; LYMPHOCYTE ACTIVATION; SYNOVITIS; T-LYMPHOCYTES;

EID: 33644521705     PISSN: 14397595     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10165-005-0452-4     Document Type: Review

References (90)

1. JJ Goronzy CM Weyand 2005 Rheumatoid arthritis Immunol Rev 204 55-73 10.1111/j.0105-2896.2005.00245.x 1:CAS:528:DC%2BD2MXkslGnsrY%3D 15790350
2. A Mor SB Abramson MH Pillinger 2005 The fibroblast-like synovial cell in rheumatoid arthritis: A key player in inflammation and joint destruction Clin Immunol 115 2 118-28 10.1016/j.clim.2004.12.009 1:CAS:528:DC%2BD2MXktVOhsb8%3D 15885632
3. R Yamada T Tanaka M Unoki T Nagai T Sawada Y Ohnishi 2001 Association between a single-nucleotide polymorphism in the promoter of the human interleukin-3 gene and rheumatoid arthritis in Japanese patients, and maximum-likelihood estimation of combinatorial effect that two genetic loci have on susceptibility to the disease Am J Hum Genet 68 3 674-85 10.1086/318789 1:CAS:528:DC%2BD3MXit1alu7k%3D 11179015
4. MJ Elliott RN Maini M Feldmann JR Kalden C Antoni JS Smolen 1994 Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis Lancet 344 8930 1105-10 1:STN:280:ByqD38%2FhslE%3D 7934491
5. B Bresnihan JM Alvaro-Gracia M Cobby M Doherty Z Domljan P Emery 1998 Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist Arthritis Rheum 41 12 2196-204 10.1002/ 1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2 1:CAS:528:DyaK1MXksl2nsw%3D%3D 9870876
6. RN Maini FC Breedveld JR Kalden JS Smolen D Davis JD Macfarlane 1998 Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis Arthritis Rheum 41 9 1552-63 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W 1:CAS:528:DyaK1cXmsVChtbg%3D 9751087
7. LW Moreland SW Baumgartner MH Schiff EA Tindall RM Fleischmann AL Weaver 1997 Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein N Engl J Med 337 3 141-7 10.1056/NEJM199707173370301 1:CAS:528:DyaK2sXlt1Smur0%3D 9219699
8. JM Bathon RW Martin RM Fleischmann JR Tesser MH Schiff EC Keystone 2000 A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis N Engl J Med 343 22 1586-93 10.1056/ NEJM200011303432201 1:CAS:528:DC%2BD3cXovVeltLg%3D 11096165
9. PE Lipsky DM van der Heijde EW St Clair DE Furst FC Breedveld JR Kalden 2000 Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group N Engl J Med 343 22 1594-602 10.1056/ NEJM200011303432202 1:CAS:528:DC%2BD3cXovVeltLk%3D 11096166
10. LW Moreland MH Schiff SW Baumgartner EA Tindall RM Fleischmann KJ Bulpitt 1999 Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial Ann Intern Med 130 6 478-86 1:CAS:528:DyaK1MXitFChs7Y%3D 10075615
11. GT Nepom P Byers C Seyfried LA Healey KR Wilske D Stage 1989 HLA genes associated with rheumatoid arthritis. Identification of susceptibility alleles using specific oligonucleotide probes Arthritis Rheum 32 1 15-21 1:STN:280:BiaC3crhtVI%3D 2492197
12. XJ Gao NJ Olsen T Pincus P Stastny 1990 HLA-DR alleles with naturally occurring amino acid substitutions and risk for development of rheumatoid arthritis Arthritis Rheum 33 7 939-46 1:STN:280:By%2BA3MvpvFI%3D 2369430
13. Y Nakai A Wakisaka M Aizawa K Itakura H Nakai A Ohashi 1981 HLA and rheumatoid arthritis in the Japanese Arthritis Rheum 24 5 722-5 1:STN:280:Bi6B3cjjsl0%3D 7236327
14. N Ohta YK Nishimura K Tanimoto Y Horiuchi C Abe Y Shiokawa 1982 Association between HLA and Japanese patients with rheumatoid arthritis Hum Immunol 5 2 123-32 10.1016/0198-8859(82)90057-X 1:STN:280:BiyD2MnjtFw%3D 6815137
15. DA Fox 1997 The role of T cells in the immunopathogenesis of rheumatoid arthritis: New perspectives Arthritis Rheum 40 4 598-609 1:STN:280:ByiB2cvivFY%3D 9125240
16. JJ Goronzy CM Weyand 2004 T-cell regulation in rheumatoid arthritis Curr Opin Rheumatol 16 3 212-7 1:CAS:528:DC%2BD2cXksFGksbw%3D 15103247
17. JA Gracie RJ Forsey WL Chan A Gilmour BP Leung MR Greer 1999 A proinflammatory role for IL-18 in rheumatoid arthritis J Clin Invest 104 10 1393-401 1:CAS:528:DyaK1MXntlyqsr4%3D 10562301
18. S Qin JB Rottman P Myers N Kassam M Weinblatt M Loetscher 1998 The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions J Clin Invest 101 4 746-54 1:CAS:528:DyaK1cXht1Wrsbk%3D 9466968
19. K Eguchi Y Ueki C Shimomura T Otsubo H Nakao K Migita 1989 Increment in the Ta1+ cells in the peripheral blood and thyroid tissue of patients with Graves' disease J Immunol 142 12 4233-40 1:STN:280:BiaB2MnmslQ%3D 2542405
20. R Gerli C Muscat A Bertotto O Bistoni E Agea R Tognellini 1996 CD26 surface molecule involvement in T-cell activation and lymphokine synthesis in rheumatoid and other inflammatory synovitis Clin Immunol Immunopathol 80 1 31-7 10.1006/clin.1996.0091 1:STN:280:BymB2MfhvFQ%3D 8674237
21. DA Hafler DA Fox ME Manning SF Schlossman EL Reinherz HL Weiner 1985 In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis N Engl J Med 312 22 1405-11 1:STN:280:BiqC1cfhsVA%3D 2985995
22. A Mizokami K Eguchi A Kawakami H Ida Y Kawabe T Tsukada 1996 Increased population of high fluorescence 1F7 (CD26) antigen on T cells in synovial fluid of patients with rheumatoid arthritis J Rheumatol 23 12 2022-6 1:STN:280:ByiC38vptlU%3D 8970035
23. C Muscat A Bertotto E Agea O Bistoni R Ercolani R Tognellini 1994 Expression and functional role of 1F7 (CD26) antigen on peripheral blood and synovial fluid T cells in rheumatoid arthritis patients Clin Exp Immunol 98 2 252-6 1:STN:280:ByqD2czlsFQ%3D 7955530
24. J Masuyama JS Berman WW Cruikshank C Morimoto DM Center 1992 Evidence for recent as well as long term activation of T cells migrating through endothelial cell monolayers in vitro J Immunol 148 5 1367-74 1:STN:280:By2C28njslU%3D 1371526
25. LJ Appleman VA Boussiotis 2003 T cell anergy and costimulation Immunol Rev 192 161-80 10.1034/j.1600-065X.2003.00009.x 1:CAS:528:DC%2BD3sXjsVOntL4%3D 12670403
26. NH Dang Y Torimoto K Shimamura T Tanaka JF Daley SF Schlossman 1991 1F7 (CD26): A marker of thymic maturation involved in the differential regulation of the CD3 and CD2 pathways of human thymocyte activation J Immunol 147 9 2825-32 1:CAS:528:DyaK38XkvVan 1717577
27. NH Dang Y Torimoto K Sugita JF Daley P Schow C Prado 1990 Cell surface modulation of CD26 by anti-1F7 monoclonal antibody. Analysis of surface expression and human T cell activation J Immunol 145 12 3963-71 1:CAS:528:DyaK3MXmtVWjtA%3D%3D 1979581
28. C Morimoto SF Schlossman 1998 The structure and function of CD26 in the T-cell immune response Immunol Rev 161 55-70 1:CAS:528:DyaK1cXitlyms7o%3D 9553764
29. C Morimoto Y Torimoto G Levinson CE Rudd M Schrieber NH Dang 1989 1F7, a novel cell surface molecule, involved in helper function of CD4 cells J Immunol 143 11 3430-9 1:CAS:528:DyaK3cXps1Ghsg%3D%3D 2479677
30. K Ohnuma Y Munakata T Ishii S Iwata S Kobayashi O Hosono 2001 Soluble CD26/dipeptidyl peptidase IV induces T cell proliferation through CD86 up-regulation on APCs J Immunol 167 12 6745-55 1:CAS:528:DC%2BD3MXptFGit7o%3D 11739489
31. K Ohnuma T Yamochi M Uchiyama K Nishibashi N Yoshikawa N Shimizu 2004 CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1 Proc Natl Acad Sci USA 101 39 14186-91 10.1073/ pnas.0405266101 1:CAS:528:DC%2BD2cXosVylsbo%3D 15353589
32. T Tanaka D Camerini B Seed Y Torimoto NH Dang J Kameoka 1992 Cloning and functional expression of the T cell activation antigen CD26 J Immunol 149 2 481-6 1:CAS:528:DyaK3sXitlWkurg%3D 1352530
33. P Naquet HR MacDonald P Brekelmans J Barbet S Marchetto W Van Ewijk 1988 A novel T cell-activating molecule (THAM) highly expressed on CD4-CD8- murine thymocytes J Immunol 141 12 4101-9 1:CAS:528:DyaL1MXlsFKgtw%3D%3D 2461984
34. S Yan D Marguet J Dobers W Reutter H Fan 2003 Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen Eur J Immunol 33 6 1519-27 10.1002/eji.200323469 1:CAS:528:DC%2BD3sXkvF2rtL4%3D 12778469
35. D Marguet L Baggio T Kobayashi AM Bernard M Pierres PF Nielsen 2000 Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26 Proc Natl Acad Sci USA 97 12 6874-9 10.1073/pnas.120069197 1:CAS:528:DC%2BD3cXktFahsb0%3D 10823914
36. B Fleischer 1994 CD26: A surface protease involved in T-cell activation Immunol Today 15 4 180-4 10.1016/0167-5699(94)90316-6 1:CAS:528:DyaK2cXis1Omu7w%3D 7911022
37. A von Bonin J Huhn B Fleischer 1998 Dipeptidyl-peptidase IV/CD26 on T cells: Analysis of an alternative T-cell activation pathway Immunol Rev 161 43-53 1:CAS:528:DyaK1cXitlyms70%3D 9553763
38. T Oravecz M Pall G Roderiquez MD Gorrell M Ditto NY Nguyen 1997 Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage J Exp Med 186 11 1865-72 10.1084/jem.186.11.1865 1:CAS:528:DyaK2sXnslGisbc%3D 9382885
39. P Proost S Struyf D Schols G Opdenakker S Sozzani P Allavena 1999 Truncation of macrophage-derived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction J Biol Chem 274 7 3988-93 10.1074/ jbc.274.7.3988 1:CAS:528:DyaK1MXhslahtb0%3D 9933589
40. KW Christopherson 2nd G Hangoc CR Mantel HE Broxmeyer 2004 Modulation of hematopoietic stem cell homing and engraftment by CD26 Science 305 5686 1000-3 10.1126/science.1097071 1:CAS:528:DC%2BD2cXmsVGmsbg%3D 15310902
41. KW Christopherson S Cooper G Hangoc HE Broxmeyer 2003 CD26 is essential for normal G-CSF-induced progenitor cell mobilization as determined by CD26-/- mice Exp Hematol 31 11 1126-34 1:CAS:528:DC%2BD3sXosVykt7o%3D 14585379
42. KW Christopherson 2nd G Hangoc HE Broxmeyer 2002 Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells J Immunol 169 12 7000-8 1:CAS:528:DC%2BD38XpsFGjsb4%3D 12471135
43. PE Wiedeman JM Trevillyan 2003 Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes Curr Opin Invest Drugs 4 4 412-20 1:CAS:528:DC%2BD3sXkvFKktbs%3D
44. S Ristic S Byiers J Foley D Holmes 2005 Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response Diabetes Obes Metab 7 6 692-8 10.1111/j.1463-1326.2005.00539.x 1:CAS:528:DC%2BD2MXht1amt73M 16219012
45. NH Dang Y Torimoto K Deusch SF Schlossman C Morimoto 1990 Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways J Immunol 144 11 4092-100 1:CAS:528:DyaK3cXksFKqu70%3D 1971293
46. NH Dang Y Torimoto SF Schlossman C Morimoto 1990 Human CD4 helper T cell activation: Functional involvement of two distinct collagen receptors, 1F7 and VLA integrin family J Exp Med 172 2 649-52 10.1084/jem.172.2.649 1:CAS:528:DyaK3cXkslKnt7c%3D 2165129
47. P Ruiz N Zacharievich L Hao AL Viciana M Shenkin 1998 Human thymocyte dipeptidyl peptidase IV (CD26) activity is altered with stage of ontogeny Clin Immunol Immunopathol 88 2 156-68 10.1006/clin.1998.4550 1:CAS:528:DyaK1cXlvVyktLw%3D 9714693
48. T Tanaka J Kameoka A Yaron SF Schlossman C Morimoto 1993 The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity Proc Natl Acad Sci USA 90 10 4586-90 1:CAS:528:DyaK3sXksVOjurg%3D 7685106
49. J Kameoka T Tanaka Y Nojima SF Schlossman C Morimoto 1993 Direct association of adenosine deaminase with a T cell activation antigen, CD26 Science 261 5120 466-9 1:CAS:528:DyaK3sXltFGhtrs%3D 8101391
50. RP Dong J Kameoka M Hegen T Tanaka Y Xu SF Schlossman 1996 Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response J Immunol 156 4 1349-55 1:CAS:528:DyaK28XpvVWksg%3D%3D 8568233
51. RP Dong K Tachibana M Hegen Y Munakata D Cho SF Schlossman 1997 Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation J Immunol 159 12 6070-6 1:CAS:528:DyaK1cXhtFKrtw%3D%3D 9550406
52. RM Goldblum FC Schmalstieg JA Nelson GC Mills 1978 Adenosine deaminase (ADA) and other enzyme abnormalities in immune deficiency states Birth Defects Orig Artic Ser 14 6A 73-84 1:CAS:528:DyaE1MXksFekurk%3D 215243
53. NH Dang FB Hagemeister M Duvic JE Romaguera A Younes D Jones 2003 Pentostatin in T-non-Hodgkin's lymphomas: Efficacy and effect on CD26+ T lymphocytes Oncol Rep 10 5 1513-8 1:CAS:528:DC%2BD3sXmvFWns7g%3D 12883733
54. Y Torimoto NH Dang E Vivier T Tanaka SF Schlossman C Morimoto 1991 Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes J Immunol 147 8 2514-7 1:CAS:528:DyaK38XkvVWj 1680916
55. T Ishii K Ohnuma A Murakami N Takasawa S Kobayashi NH Dang 2001 CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO Proc Natl Acad Sci USA 98 21 12138-43 10.1073/pnas.211439098 1:CAS:528:DC%2BD3MXns1Cjsbo%3D 11593028
56. S Kobayashi K Ohnuma M Uchiyama K Iino S Iwata NH Dang 2004 Association of CD26 with CD45RA outside lipid rafts attenuates cord blood T-cell activation Blood 103 3 1002-10 1:CAS:528:DC%2BD2cXhtVaksrc%3D 14525771
57. S Iwaki-Egawa Y Watanabe Y Kikuya Y Fujimoto 1998 Dipeptidyl peptidase IV from human serum: Purification, characterization, and N-terminal amino acid sequence J Biochem (Tokyo) 124 2 428-33 1:CAS:528:DyaK1cXmtlSrs7c%3D
58. C Durinx AM Lambeir E Bosmans JB Falmagne R Berghmans A Haemers 2000 Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides Eur J Biochem 267 17 5608-13 10.1046/ j.1432-1327.2000.01634.x 1:CAS:528:DC%2BD3cXmsVenu7o%3D 10951221
59. T Tanaka JS Duke-Cohan J Kameoka A Yaron I Lee SF Schlossman 1994 Enhancement of antigen-induced T-cell proliferation by soluble CD26/ dipeptidyl peptidase IV Proc Natl Acad Sci USA 91 8 3082-6 1:CAS:528:DyaK2cXkvVSrt7g%3D 7909158
60. JR Glenney Jr 1989 Tyrosine phosphorylation of a 22-kDa protein is correlated with transformation by Rous sarcoma virus J Biol Chem 264 34 20163-6 1:CAS:528:DyaL1MXmtFalt7c%3D 2479645
61. KG Rothberg JE Heuser WC Donzell YS Ying JR Glenney RG Anderson 1992 Caveolin, a protein component of caveolae membrane coats Cell 68 4 673-82 10.1016/0092-8674(92)90143-Z 1:CAS:528:DyaK38XhvFWnurY%3D 1739974
62. E Yamada 1955 The fine structure of the gall bladder epithelium of the mouse J Biophys Biochem Cytol 1 5 445-58 1:STN:280:CymD3MrisFA%3D 13263332
63. EJ Smart GA Graf MA McNiven WC Sessa JA Engelman PE Scherer 1999 Caveolins, liquid-ordered domains, and signal transduction Mol Cell Biol 19 11 7289-304 1:CAS:528:DyaK1MXmvFeksbw%3D 10523618
64. B Razani JA Engelman XB Wang W Schubert XL Zhang CB Marks 2001 Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities J Biol Chem 276 41 38121-38 1:CAS:528:DC%2BD3MXotFOrurk%3D 11457855
65. B Razani XB Wang JA Engelman M Battista G Lagaud XL Zhang 2002 Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolae Mol Cell Biol 22 7 2329-44 10.1128/ MCB.22.7.2329-2344.2002 1:CAS:528:DC%2BD38Xit1Kit7k%3D 11884617
66. F Galbiati JA Engelman D Volonte XL Zhang C Minetti M Li 2001 Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and t-tubule abnormalities J Biol Chem 276 24 21425-33 10.1074/jbc.M100828200 1:CAS:528:DC%2BD3MXksFGlurw%3D 11259414
67. PE Scherer T Okamoto M Chun I Nishimoto HF Lodish MP Lisanti 1996 Identification, sequence, and expression of caveolin-2 defines a caveolin gene family Proc Natl Acad Sci USA 93 1 131-5 10.1073/ pnas.93.1.131 1:CAS:528:DyaK28Xjslyjtw%3D%3D 8552590
68. PE Scherer Z Tang M Chun M Sargiacomo HF Lodish MP Lisanti 1995 Caveolin isoforms differ in their N-terminal protein sequence and subcellular distribution. Identification and epitope mapping of an isoform-specific monoclonal antibody probe J Biol Chem 270 27 16395-401 1:CAS:528:DyaK2MXmvVGntLo%3D 7608210
69. J Couet S Li T Okamoto T Ikezu MP Lisanti 1997 Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins J Biol Chem 272 10 6525-33 1:CAS:528:DyaK2sXhvVOlsro%3D 9045678
70. P Gargalovic L Dory 2003 Caveolins and macrophage lipid metabolism J Lipid Res 44 1 11-21 1:CAS:528:DC%2BD3sXlslOiuw%3D%3D 12518018
71. D Riemann GH Hansen L Niels-Christiansen E Thorsen L Immerdal AN Santos 2001 Caveolae/lipid rafts in fibroblast-like synoviocytes: ectopeptidase-rich membrane microdomains Biochem J 354 Pt 1 47-55 1:CAS:528:DC%2BD3MXhslSjurk%3D 11171078
72. SE Woodman AW Ashton W Schubert H Lee TM Williams FA Medina 2003 Caveolin-1 knockout mice show an impaired angiogenic response to exogenous stimuli Am J Pathol 162 6 2059-68 1:CAS:528:DC%2BD3sXkvVyjt7g%3D 12759260
73. J Liu XB Wang DS Park MP Lisanti 2002 Caveolin-1 expression enhances endothelial capillary tubule formation J Biol Chem 277 12 10661-8 1:CAS:528:DC%2BD38XisVyksb4%3D 11748236
74. M Bucci JP Gratton RD Rudic L Acevedo F Roviezzo G Cirino 2000 In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation Nat Med 6 12 1362-7 1:CAS:528:DC%2BD3cXosl2hs78%3D 11100121
75. HC Cheng M Abdel-Ghany RC Elble BU Pauli 1998 Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin J Biol Chem 273 37 24207-15 10.1074/jbc.273.37.24207 1:CAS:528:DyaK1cXmtFOrtrs%3D 9727044
76. HC Cheng M Abdel-Ghany BU Pauli 2003 A novel consensus motif in fibronectin mediates dipeptidyl peptidase IV adhesion and metastasis J Biol Chem 278 27 24600-7 10.1074/jbc.M303424200 1:CAS:528:DC%2BD3sXltVSmurs%3D 12716896
77. S Wrenger J Faust C Mrestani-Klaus A Fengler A Stockel-Maschek S Lorey 2000 Down-regulation of T cell activation following inhibition of dipeptidyl peptidase IV/CD26 by the N-terminal part of the thromboxane A2 receptor J Biol Chem 275 29 22180-6 1:CAS:528:DC%2BD3cXlt1ehur0%3D 10896952
78. C Herrera C Morimoto J Blanco J Mallol F Arenzana C Lluis 2001 Comodulation of CXCR4 and CD26 in human lymphocytes J Biol Chem 276 22 19532-9 10.1074/jbc.M004586200 1:CAS:528:DC%2BD3MXkt12rt7Y%3D 11278278
79. R Montesano J Roth A Robert L Orci 1982 Non-coated membrane invaginations are involved in binding and internalization of cholera and tetanus toxins Nature 296 5858 651-3 10.1038/296651a0 1:STN:280:Bi2C2szhslI%3D 7070509
80. L Pelkmans A Helenius 2002 Endocytosis via caveolae Traffic 3 5 311-20 10.1034/j.1600-0854.2002.30501.x 1:CAS:528:DC%2BD38XjvFCgtb4%3D 11967125
81. A Grakoui SK Bromley C Sumen MM Davis AS Shaw PM Allen 1999 The immunological synapse: A molecular machine controlling T cell activation Science 285 5425 221-7 10.1126/science.285.5425.221 1:CAS:528:DyaK1MXks1SjsLg%3D 10398592
82. SJ Turley K Inaba WS Garrett M Ebersold J Unternaehrer RM Steinman 2000 Transport of peptide-MHC class II complexes in developing dendritic cells Science 288 5465 522-7 10.1126/science.288.5465.522 1:CAS:528:DC%2BD3cXivVOrsL0%3D 10775112
83. FM Brennan AL Hayes CJ Ciesielski P Green BM Foxwell M Feldmann 2002 Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: Involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis Arthritis Rheum 46 1 31-41 10.1002/ 1529-0131(200201)46:1<31::AID-ART10029>3.0.CO;2-5 1:CAS:528:DC%2BD38Xht1WlurY%3D 11822409
84. JM Kremer R Westhovens M Leon E Di Giorgio R Alten S Steinfeld 2003 Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig N Engl J Med 349 20 1907-15 10.1056/NEJMoa035075 1:CAS:528:DC%2BD3sXptVGnurs%3D 14614165
85. LW Moreland R Alten F Van den Bosch T Appelboom M Leon P Emery 2002 Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion Arthritis Rheum 46 6 1470-9 10.1002/art.10294 1:CAS:528:DC%2BD38Xltlanurs%3D 12115176
86. T Lindsten KP Lee ES Harris B Petryniak N Craighead PJ Reynolds 1993 Characterization of CTLA-4 structure and expression on human T cells J Immunol 151 7 3489-99 1:CAS:528:DyaK2cXmtlyl 8397258
87. GJ Freeman JG Gribben VA Boussiotis JW Ng VA Restivo Jr LA Lombard 1993 Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T cell proliferation Science 262 5135 909-11 1:CAS:528:DyaK2cXhtVChtLc%3D 7694363
88. JF Brunet F Denizot MF Luciani M Roux-Dosseto M Suzan MG Mattei 1987 A new member of the immunoglobulin superfamily - CTLA-4 Nature 328 6127 267-70 10.1038/328267a0 1:CAS:528:DyaL2sXmtFaktL0%3D 3496540
89. PS Linsley JL Greene W Brady J Bajorath JA Ledbetter R Peach 1994 Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors Immunity 1 9 793-801 10.1016/ S1074-7613(94)80021-9 1:CAS:528:DyaK2MXislWktLo%3D 7534620
90. GJ Freeman F Borriello RJ Hodes H Reiser KS Hathcock G Laszlo 1993 Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice Science 262 5135 907-9 1:CAS:528:DyaK3sXms1ynu7Y%3D 7694362